The report forecasts the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020.
Commenting on the report, an analyst from the research team said: Emergence of biosimilars will be a key trend for market growth. The sales of biologics are expected to decline during the forecast period, owing to the increased sales of their biosimilar versions, which cost lesser and are almost similar to their originator biologic compounds. For instance, epoetin alfa BS injection by JCR Pharmaceuticals and Kissei Pharmaceutical is a biosimilar form of epoetin alfa that was launched in the market in May 2010. Similarly, the US FDA approved Inflectra in April 2016 to treat autoimmune and inflammatory diseases.
According to the report, Reimbursement benefits for biosimilars will be a key driver for market growth. Lack of cost-effectiveness impeding the coverage of drugs results in variations in the reimbursement status of drugs from region to region. The Medicare and Medicaid reimbursement plans are expected to have an impact on the global scenario for diseases such as diabetes, which have high prevalence and incidence rates in the US. Medicare provides coverage for the older population (65 years or older), people with the end-stage renal disease (ESRD), and people aged below 65 years with certain disabilities.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Companies Mentioned Include:
- Teva Pharmaceuticals
- Dr Reddy's
- Coherus Biosciences
- Daiichi Sankyo
- Emcure Pharmaceuticals
- Gedeon Richter
- GeneScience Pharmaceuticals
- Hetero Drugs
- Samsung Biologics
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
PART 07: Market segmentation by application
PART 08: Market segmentation by end-user
PART 09: Geographical segmentation
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
PART 16: Appendix
PART 17: About the Author
For more information about this report visit http://www.researchandmarkets.com/research/qq862c/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-biosimilars-market-cagr-growth-of-5552-by-2020---trends-technologies--opportunities-report-2016-2020---key-vendors-3sbio-aspen-sanofi-300313288.html
SOURCE Research and Markets